Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | IDH2 | P48735 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 7/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815472 | 0.86 | HRH3 (0.38) | PHGDHHRH3DRD2DRD3ACACB | |
| SCHEMBL14815124 | 0.86 | IDO1 (0.35) | HCRTR2IDH2DRD2HCRTR1 | |
| SCHEMBL14814765 | 0.85 | HCRTR1 (0.41) | PHGDHHRH3HCRTR2IDH2DRD2 | |
| SCHEMBL14815323 | 0.81 | HCRTR2 (0.43) | HRH3HCRTR2IDH2DRD2HCRTR1 | |
| SCHEMBL14815100 | 0.77 | HCRTR2 (0.41) | HCRTR2DRD2HCRTR1ACACB | |
| SCHEMBL14815443 | 0.76 | HCRTR2 (0.40) | HCRTR2IDH2HCRTR1 | |
| SCHEMBL14815301 | 0.76 | EPHX2 (0.41) | HCRTR2HCRTR1 | |
| SCHEMBL14815213 | 0.75 | HCRTR2 (0.41) | HRH3HCRTR2IDH2DRD2DRD3 | |
| SCHEMBL14815318 | 0.74 | HCRTR2 (0.38) | HCRTR2HCRTR1 | |
| SCHEMBL30582911 | 0.71 | HRH3 (0.52) | PHGDHHRH3DRD2DRD3ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | PHGDH 3730/4885HRH3 1244/4885HCRTR2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.